Life Sciences

Skyrizi’s Breakthrough: Promising Results in Ulcerative Colitis Maintenance Study Pave the Way for FDA Approval

Skyrizi’s Breakthrough: Promising Results in Ulcerative...

Jun 19, 2023

AbbVie’s Skyrizi has posted another victory in a maintenance trial after complet...

Mersana Hit With Another FDA Hold Linked to Patient Fatality

Mersana Hit With Another FDA Hold Linked to Patient Fat...

Jun 17, 2023

An additional FDA hold has been placed on Mersana Therapeutics in connection wit...

Novartis Secures $3.2 Billion Acquisition of Chinook to Enhance Kidney Disease Strategy

Novartis Secures $3.2 Billion Acquisition of Chinook to...

Jun 15, 2023

Novartis, the Swiss pharmaceutical giant, is set to bolster its kidney disease p...

AstraZeneca Invests $85M in Quell for “One and Done” Cell Therapy to Combat Type 1 Diabetes

AstraZeneca Invests $85M in Quell for “One and Done” Ce...

Jun 13, 2023

AstraZeneca has entered the field of autoimmune cell therapy by partnering with ...

Cue Health racks up FDA’s first de novo nod for an at-home COVID test

Cue Health racks up FDA’s first de novo nod for an at-h...

Jun 13, 2023

Cue Health has received the FDA’s first approval for regular use of a COVID-19 a...

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

Commercial Excellence Summit Brings Together Leading Mi...

Jun 13, 2023

This week is set to be a pivotal one in the life sciences industry. Leading mind...

Bon Secours Mercy Health And Anthem BCBS Lock Horns Over Contract Negotiations

Bon Secours Mercy Health And Anthem BCBS Lock Horns Ove...

Jun 13, 2023

Bon Secours Mercy Health is locking horns with Anthem Blue Cross and Blue Shield...

GSK’s Adult Shot Arexvy Bags European Approval

GSK’s Adult Shot Arexvy Bags European Approval

Jun 9, 2023

With Arexvy, GSK has achieved the same status in Europe as it did with the desir...

Japanese drugmaker Eisai undergoing investigation for ransomware attack

Japanese drugmaker Eisai undergoing investigation for r...

Jun 9, 2023

Following the recent trend among Japanese firms, such as West Japan Railway, Tok...

FibroGen’s DMD drug fails phase 3 clinical trial, adding to clinical troubles

FibroGen’s DMD drug fails phase 3 clinical trial, addin...

Jun 9, 2023

FibroGen continues to face challenges in its clinical endeavors, now extending i...

Bayer enters agreement with Acuitas for its gene editing delivery tech

Bayer enters agreement with Acuitas for its gene editin...

Jun 9, 2023

German drugmaker Bayer has entered an agreement with Acuitas Therapeutics, the f...

Arvinas to Expand Development of Resistance-Busting Cancer Drug

Arvinas to Expand Development of Resistance-Busting Can...

Jun 9, 2023

Arvinas is moving forward with its plans to expand the development of its ARV-76...

Novartis spinoff Sandoz to establish HQ in Basel

Novartis spinoff Sandoz to establish HQ in Basel

Jun 7, 2023

Novartis’ generics spinoff, Sandoz, has announced that it will be setting up its...

Novartis drug helps stop breast cancer’s return in a large study

Novartis drug helps stop breast cancer’s return in a la...

Jun 7, 2023

According to clinical study findings, when administered following surgery in adu...

AstraZeneca Adds Imfinzi and Lynparza to Ovarian Cancer Treatment

AstraZeneca Adds Imfinzi and Lynparza to Ovarian Cancer...

Jun 7, 2023

AstraZeneca’s usage limitation in ovarian cancer has been a stumbling block desp...

FDA clears narrow use of prostate cancer therapy Lynparza

FDA clears narrow use of prostate cancer therapy Lynparza

Jun 7, 2023

Lynparza can now be used in conjunction with Zytiga from Johnson & Johnson and a...

27
28
29
30
31